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Abstract
Background: Recent guidelines recommend monitor-
ing for opioid and drug use in patients with chronic
pain to detect use of undisclosed or illicit substances,
and to determine compliance with prescribed medi-
cations. We examined the technical and clinical
impact of drug testing for patients on chronic pain
therapy in our clinical laboratory.
Methods: Testing volumes were obtained for 4 years.
Volumes from three recent months were also exam-
ined in detail to determine average turnaround time,
assay performance (i.e., number of positive screening
and confirmatory tests and testing discrepancies) and
consistency of patient results with medication history.
Results: Our testing volume continues to grow signif-
icantly, especially in the primary care setting, with an
average yearly increase of 34%. Approximately 70%
of patients confirmed positive for an opioid. Other
drugs were positive in -30% of patients. Twenty-nine
percent of patients tested positive for a medication
without a prescription. Overall, the compliance rate
was 85% indicating that 15% of patients had negative
test results despite being prescribed a chronic pain
medication.
Conclusions: Clinical laboratories should consider the
impact of these guidelines and examine options to
optimize testing such as limiting or modifying the test
panel.
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Introduction
Current published guidelines recommend periodic
monitoring for opioid and drug use in patients with
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chronic non-cancer pain (1, 2). According to these
guidelines, drug testing should be performed to iden-
tify use of undisclosed substances, uncover diversion
of prescribed substances, and determine compliance
with prescribed substances. A specific testing panel is
not recommended by these guidelines, and the time
interval between testing depends on the specific cir-
cumstances of a given patient. Initial testing to detect
illicit drug use may be performed using class-specific
immunoassay panels that do not identify individual
drugs within each class. However, the guidelines state
that initial testing should be followed with a specific
confirmatory technique such as gas chromatography/
mass spectrometry or liquid chromatography/tandem
mass spectrometry to identify, or confirm, the pres-
ence or absence of a specific drug and/or its meta-
bolite(s).
Several articles have summarized drug testing
results in chronic pain patients. These publications
stress the need for stringent screening programs as
recommended by recent guidelines (2–9). Michna and
colleagues found that 45% of patients had urine
results that were not consistent with their prescribed
medications and 20% had illicit substances in their
urine (8). The 2007 annual report from the American
Association of Poison Control Centers confirms the
high rate of abuse of analgesics and other substances
in the population in general (10).
Clinical laboratories will be affected by these recom-
mendations to varying degrees, depending upon their
patient population and their clinical interpretation of
the guidelines. Testing volumes, breadth of test
menu, specimen processing requirements, turn-
around time, result interpretation, and cost need to be
considered. For example, many hospital laboratories
have the capability to perform in-house urine drug
screening for their emergency department, however,
the components and cut-offs of screening panels may
be different for patients on chronic pain therapy com-
pared with emergency department patients. Also, it
may not be feasible to perform the additional screen-
ing tests in-house (11, 12). Most laboratories do not
have the resources to perform confirmatory testing
and outsource this testing to a reference laboratory.
Testing performed by reference laboratories is costly,
especially when large numbers of confirmations are
necessary. In addition, the demand for specialized
testing increases to accommodate the prescribed
medications.
In recent years, the clinical laboratory at Brigham
and Women’s Hospital, which services a large aca-
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Table 1 Current test panel for patients on chronic pain therapya.
Test Cut-off for Cut-off for
screening test confirmation test
6-MAMb Not performedc 10 ng/mL
Amphetamine 1000 ng/mL 50 ng/mL
Barbiturates 200 ng/mL 100 ng/mL
Benzodiazepines 200 ng/mL 100 ng/mL
Buprenorphine Not performedc 5 ng/mL
Cocaine metabolite 300 ng/mL 50 ng/mL
Ethanol 10 mg/dL Not performed
Fentanyl Not performed 1 ng/mL
MDMA 500 ng/mL 50 ng/mL
Methadone 300 ng/mL 100 ng/mL
Opioids 300 ng/mL 100 ng/mL
PCP 25 ng/mL 25 ng/mL
Propoxyphene 300 ng/mL 300 ng/mL
THC 50 ng/mL 3 ng/mL
Tramadol Not performedc 100 ng/mL
aScreens and/or confirmations in bold-faced are performed on every specimen. Screens and/or confirmations not in bold-
faced are performed under special conditions or when the screen is positive. b6-MAM is performed only in specimens, which
are positive for morphine. cScreening assays are available, but were not performed. 6-MAM, 6-monoacetylmorphine;MDMA,
methylenedioxymethamphetamine; PCP, phencyclidine; THC, tetrahydrocannabinol.
demic medical center, has seen a marked increase in
the number of requests for urine drug testing in
patients on chronic pain therapy along with an expan-
sion of the testing requested beyond that currently
offered and performed in the laboratory. We reviewed
the clinical and technical impact of drug testing on
our clinical laboratory.
Materials and methods
The clinical laboratory at Brigham and Women’s Hospital
currently sends specimens from patients on chronic pain
therapy to a reference laboratory for both initial and confirm-
atory testing. The pain clinic at Brigham and Women’s Hos-
pital manages the majority of patients on therapy for chronic
pain, and in conjunction with the laboratory, has constructed
an appropriate panel consistent with their interpretation of
the recent guidelines (Table 1). Drugs such as benzodiaze-
pines, fentanyl, methadone, opioids and tramadol are pre-
scribed for chronic pain and are typically monitored to
assess compliance or uncover potential diversion. We per-
form testing for all substances listed in Table 1 in order to
discover the use of illicit or undisclosed substances. These
substances may be obtained illegally by patients or may
have been prescribed by a clinician other than the one order-
ing the testing.
The initial screening panel is performed by our primary
reference laboratory using an enzyme multiplied immuno-
assay technique (EMIT) II plus (Siemens Medical Solutions
Diagnostics, Tarrytown, NY, USA) on an Olympus AU400e
analyzer (Olympus America Inc, Center Valley, PA, USA).
Qualitative screening results are reported for amphetamine,
barbiturates, benzodiazepines, cocaine metabolite, ethanol,
methylenedioxymethamphetamine (MDMA), methadone,
opioids, phencyclidine (PCP), propoxyphene and tetrahydro-
cannabinol (THC). Corresponding screening cut-offs are
listed in Table 1. In general, confirmations are performed by
gas chromatography/mass spectrometry or liquid chroma-
tography/tandem mass spectrometry only when screening
results are positive. However, due to the low cross-reactivity
of the opioid assay for oxycodone and oxymorphone, con-
firmations for opioids are performed on all patient speci-
mens regardless of the screen results. In addition, a
screening assay for 6-monoacetylmorphine (6-MAM) is per-
formed only in patients with positive morphine results in
order to evaluate recent heroin use.
We retrospectively examined the pattern of urine drug
testing for patients on chronic pain therapy in our laboratory.
Test volumes were gathered from January 2005 to Decem-
ber 2008. We included the percentage of tests ordered from
our pain clinic vs. other areas, such as primary care. Three
months (March, April and May 2008) were examined in more
detail to determine average turnaround time, number of
positive confirmatory tests, the number of false positive
and false negative screening results and any testing
discrepancies.
Correlations with patient medication and clinical history
were performed using our electronic medical record to deter-
mine if results were consistent with prescribed medications.
Considering drug metabolism pathways and differential
specificity of the opioid screen assay, oxycodone and oxy-
morphone, morphine and codeine, and hydrocodone and
hydromorphone were grouped together in the data analysis
(Figure 1).
We took into account the technical performance of
the assays when determining whether or not the clinical
medication history was consistent with the test results. For
example, when using the EMIT assay, patients taking their
prescribed dose of clonazepam or lorazepam may have had
a negative benzodiazepine screen result due to the low
cross-reactivity of the assay for these medications. If a nega-
tive screening result in a patient prescribed a medication
could be explained by the technical performance of the
assay, the results were considered consistent. In addition,
both negative and positive results in patients taking medi-
cations on an ‘‘as needed’’ basis were considered consistent.
We could not take into account an inherent limitation of
urine drug testing. Negative results even with highly sensi-
tive, quantitative assays cannot confirm that a patient is not
taking their prescribed medication. For example, patients
with unusual drug metabolism such as that seen with genet-
ic variations in drug metabolizing enzymes, can show
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Figure 1 Opioid metabolism.
(A) Metabolic pathways of morphine and its derivatives. (B) Metabolic pathway of oxycodone and its primary metabolite.
Figure 2 Yearly test volumes.
The yearly test volumes from our pain clinic (solid bars) and
other hospital areas (diagonally striped bars) are plotted
from 2005 to 2008.
negative screening results, despite compliance with medi-
cation use (13).
Results
The average turnaround time for all final results was
9.9, 11.1 and 9.6 days for March, April and May 2008,
respectively. The test panel is extensive and includes
assays such as buprenorphine, fentanyl and tramadol
(Table 1) that are specific for monitoring pain man-
agement patients. Due to an increasing test volume,
the number of specialized tests requested, and the
fact that we do not perform testing in-house, the cost
to our laboratory is high.
The test volumes have increased yearly from the
pain clinic as well as from other areas of the hospital
such as primary care (Figure 2). The number of spec-
imens with orders for the chronic pain panel
increased by an average of 34% per year from 2005
through 2008. The percentage of panels ordered by
services other than the pain clinic increased signifi-
cantly from an average of 3% in 2005, 2006 and 2007
to 10% in 2008.
The percentage of patients with both screen and
confirmed positive test results for each drug or class
of drugs was determined using 3 months of recent
data (Table 2). Approximately 70% of patients con-
firmed positive for an opioid. Of these patients, 46%
tested positive for oxycodone and/or oxymorphone,
24% tested positive for morphine and/or codeine and
17% tested positive for hydrocodone and/or hydro-
morphone. These results indicate that patients were
taking multiple opioids simultaneously. Approxim-
ately 20% of patients were positive for methadone
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Table 2 Patients testing positive by drug screening and/or confirmatory testing.
Drug % of patients with a % of patients with a
positive screening positive confirmatory
result (total number)a result (total number)a
Opioid 53.6 (218) 69.5 (283)b
Oxycodone, oxymorphone 31.0 (126) 46.2 (188)b
Morphine, codeine 23.6 (96) 23.8 (97)b
Hydromorphone, hydrocodone 17.2 (70) 17.2 (70)b
Methadone 22.1 (90) 21.9 (89)
Benzodiazepines 16.7 (68) 14.5 (59)
Fentanyl Not performed 12.5 (51)
THC 6.1 (25) 6.1 (25)
Tramadol 4.9 (20) Not performed
MDMA 4.7 (19) 0.0 (0)
Barbiturates 4.4 (18) 4.4 (18)
Buprenorphine Not performed 4.7 (19)
Cocaine 3.2 (13) 3.2 (13)
Ethanol 1.5 (6) Not performed
Amphetamine 1.0 (4) 1.0 (4)
Propoxyphene 1.0 (4) 0.7 (3)
6-MAM Not performed 0.2 (1)
PCP 0.2 (1) 0.0 (0)
aPercentage based on a total of 407 patients. bOpioid confirmation was performed on all specimens regardless of screen
result. Due to technical performance of opioid screen, screen result may be negative when opioid present. Patients may test
positive for more than one group of opioids, therefore, the absolute numbers are not additive. THC, tetrahydrocannabinol;
MDMA, methylenedioxymethamphetamine; 6-MAM, 6-monoacetylmorphine; PCP, phencyclidine.
and ;15% were positive for benzodiazepines and
fentanyl. Less than 10% of patients were positive for
amphetamine, barbiturates, buprenorphine, cocaine,
ethanol, 6-MAM, MDMA, PCP, propoxyphene, THC
and tramadol. We found that 10% of patients had no
drugs detected in their specimen.
False positive screening results with immunoassays
can be obtained due to cross-reactivity with structur-
ally related drugs outside the target class. The 19
positive screening results for MDMA and one positive
screening result for PCP could not be confirmed with
gas chromatography/mass spectrometry (Table 2).
The false positive results were due primarily to over-
the-counter medications such as pseudoephedrine.
Twenty-five percent (1 out of 4) of screening results
for propoxyphene were falsely positive as were 13%
(9 out of 68) of benzodiazepines. False positive results
were infrequently seen with methadone and opioids.
No other drugs produced false positive screens
during the examination of 3 months of data.
The number of false negative opioid screening
results was apparent because, unlike the testing pro-
tocol for other drugs, opioid confirmations were per-
formed on all patients regardless of screen results.
One patient who had a positive confirmatory test for
morphine and/or codeine had a negative screen,
while sixty-two patients who had a positive confirm-
atory test for oxycodone and/or oxymorphone had a
negative screen result (Table 2).
The confirmed positive test results were compared
to the list of prescribed medications in the electronic
medical record for all patients (Tables 3 and 4). Over-
all, ;85% of patients with a prescription for a partic-
ular medication tested positive for that medication
(Table 3). The compliance rate based on an individual
drug was )80%, with the exception of tramadol
which was 74%. Nine patients (2.3%) tested negative,
even though they were prescribed more than one
drug. Tramadol, morphine and codeine, and fentanyl
showed the highest non-compliance rate or potential
for drug diversion with 26.3%, 16.1% and 14.5%
of patients not taking the prescribed medication,
respectively.
Of all patients tested, 28.7% tested positive for at
least one drug or medication they were not prescribed
(i.e., potential drug abuse) (Table 4). The potential
abuse rate for morphine and codeine, THC and ben-
zodiazepines was 5%–10%. Twenty-eight patients
(9.3%) were potentially abusing more than one drug.
Eleven patients (2.7%) had more than one incident in
which non-prescribed medications were detected in
their urine.
Discussion
While the turnaround time for results for patients on
chronic therapy is not as critical as for patients in the
emergency department, it is important to have the
results in a timely manner (i.e., within 1 week).
Clinicians may be waiting for results to determine
patient acceptance into the program or to decide
whether to refill a prescription. As encountered in our
laboratory, turnaround time may be longer than a
week due to the need to send the specimen for testing
at a reference laboratory. If turnaround time is unac-
ceptable to clinicians, the clinical laboratory should
consider performing some or all testing in-house.
We observed an average annual increase of 34% in
yearly test volumes between 2005 and 2008. We can
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Table 3 Percentage of patients taking prescribed medications.
Drug (number of prescriptions) % patients with prescription % patients with
for a medication that prescription for a
appropriately shows up in medication missing
drug testb in drug test
All drugs (ns387) 85.3 14.7
Oxycodone, oxymorphone (ns254) 93.3 6.7
Morphine, codeine (ns87) 83.9 16.1
Hydromorphone, hydrocodone (ns69) 88.4 11.6
Methadone (ns85) 95.3 4.7
Benzodiazepines (ns100) 91.0 9.0
Fentanyl (ns55) 85.5 14.5
THC (in the form of marinol) (ns5) 100.0 N/A
Tramadol (ns19) 73.7 26.3
MDMAa (ns0) N/A N/A
Barbiturate (ns9) 88.9 11.1
Buprenorphinea (ns0) N/A N/A
Cocainea (ns0) N/A N/A
Ethanola (ns0) N/A N/A
Amphetaminea (ns0) N/A N/A
Propoxyphene (ns3) 100.0 N/A
6-MAMa (ns0) N/A N/A
PCPa (ns0) N/A N/A
aDrugs not prescribed by physicians at the Pain Clinic. bAs described in the Materials and methods section, confirmed negative
tests are seen in both compliant and non-compliant patients. THC, tetrahydrocannabinol; MDMA, methylenedioxy-
methamphetamine; 6-MAM, 6-monoacetylmorphine; PCP, phencyclidine.
Table 4 Patients testing positive for a drug or medication
without a prescription.





















aDrugs not prescribed by physicians at the Pain Clinic. THC,
tetrahydrocannabinol; MDMA, methylenedioxymethamphe-
tamine; 6-MAM, 6-monoacetylmorphine; PCP, phencyclidine.
attribute the increase in test volume to multiple fac-
tors over the past several years, including the pub-
lished guidelines, data from literature cited in this
study and fear of prescribing narcotics to addicts or
patients abusing the system. Primary care and inter-
nal medicine clinicians are realizing the importance of
screening patients as evidenced by the increase in the
number of specimens received from areas other than
the pain clinic. Furthermore, our hospital is in the pro-
cess of implementing guidelines for monitoring
patients on chronic pain therapy which will include
clinical laboratory testing.
From the additional testing in patients on chronic
pain therapy, clinical laboratories can expect an
increase in cost related to the increase in the number
of positive results for some drugs or classes of drugs.
Different screening and confirmatory methods must
be performed to cover the breadth of the chronic pain
panel. For example, five different immunoassays are
currently necessary to screen for morphine, heroin,
tramadol, fentanyl and buprenorphine because there
is a lack of cross-reactivity in the current assays as
well as separate confirmatory tests. This testing
increases the cost considerably. For laboratories that
would like to perform the testing in-house, or are
examining cost saving opportunities, the percentage
of positive drug test results are useful for determining
testing logistics. Virtually no patients were positive
for 6-MAM (which only confirms recent heroin use
within the past 6–8 h), MDMA, and PCP. To decrease
cost, testing for 6-MAM, MDMA, and PCP may not be
necessary or could be limited to only those patients
with a high likelihood of recent use. However, differ-
ences in patterns in drug use across the US should
be considered. Confirmatory testing is typically more
expensive than screening and more difficult to imple-
ment. Utilizing a low cost but sensitive screening test,
if available, would also decrease the cost of testing.
As evidenced by the number of false negative results,
the opioid screen used by our reference laboratory
is not sensitive to oxycodone or oxymorphone. An
immunoassay screen specific for oxycodone is now
available and could obviate the need for and cost of
opiate confirmations in all patient specimens. In
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addition, confirmation of all results may not be neces-
sary if the screening results are consistent with the
patient’s medications.
Our clinical laboratory frequently receives requests
from physicians, particularly those who lack expertise
in pain management, to help with result interpreta-
tion. This may be related to the increase in the num-
ber of positive results and the fact that patient
management is closely tied to these test results.
Other laboratories may also expect an increase in the
number of inquiries and should be prepared to
educate technical and medical staff and help with
interpretation of test results. An important aspect of
result interpretation is to understand that the cross-
reactivity (i.e., the amount of drug required to trigger
a positive result) depends upon which drug in the
class is present and the immunoassay technique util-
ized by the laboratory. The results obtained with the
EMIT assay, used by our reference laboratory, may
not be the same as those obtained by laboratories
using different assay methods. Laboratory directors
should understand the performance of their particular
assays and communicate this to the clinicians.
We found that ;15% of patients were not taking
their prescribed medication or potentially diverting it,
and ;30% were potentially abusing drugs. According
to the medical records, suspicion for diversion was
low. Tramadol showed the highest rate of non-
compliance. However, this result may be skewed due
to the low number of patients. In addition, drug use
is specific by region; our results may not be applica-
ble to other populations of chronic pain patients. The
high potential abuse rate for benzodiazepines and
opioids may be due to high prescription frequency
and wide availability of these drugs. Similar to the
general population, patients in chronic pain common-
ly abuse THC. The abuse rate for illicit drugs such
as heroin (as reflected by 6-MAM), amphetamines,
cocaine, PCP and MDMA was relatively low in this
patient population and is consistent with our sugges-
tion to eliminate screening for these drugs. Overall,
our findings suggest that a targeted and cost-effective
comprehensive panel to detect compliance, diversion
and/or use of undisclosed substances is warranted in
chronic pain patients regardless of their medication
history.
The addition of testing from patients on chronic
pain therapy has increased the complexity of our test
menu and has had a significant technical and clinical
impact on our laboratory. We are in the process of
implementing some of the suggestions mentioned
above. To aid with test interpretation, we are prepar-
ing guidelines that will indicate the drugs that can or
cannot be detected by each immunoassay, and the
criteria for confirmatory testing. In addition, we are
limiting the test panel, implementing an oxycodone
specific immunoassay screen and performing testing
in-house to optimize the testing algorithm and reduce
the financial burden.
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